Filing Overview
This Form 6-K, filed January 10, 2023, furnishes unaudited interim financial statements for Happiness Development Group Limited for the six months ended September 30, 2022, with comparative information for the six months ended September 30, 2021. The request identifies Paranovus Entertainment Technology Ltd.; however, the filing’s registrant is Happiness Development Group Limited.
Financial Performance and Position
- Revenue: $52.99 million, up 13.0% from $46.88 million, driven primarily by healthcare products and automobile sales. E-commerce revenue declined to $8.85 million from $29.63 million following the disposal of certain low-margin, loss-making subsidiaries.
- Gross profit and margin: Gross profit was $2.53 million versus $5.67 million. Gross margin declined to 4.8% from 12.1%, as cost of revenue increased 22.4% to $50.46 million.
- Operating expenses: Total operating expenses increased 36.1% to $22.06 million. Selling and marketing expense rose 53.2% to $17.82 million, while research and development expense declined 49.0% to $0.40 million.
- Operating loss: The income statement reports an operating loss of $19.53 million, compared with an operating loss of $10.53 million in the prior period. The narrative contains an inconsistent reference to 2021 operating income.
- Net loss: Net loss was $22.74 million, compared with $10.54 million of net income in the prior period. Net loss attributable to the company was $19.37 million versus $10.05 million.
- Comprehensive loss: Comprehensive loss attributable to the company was $27.43 million, including a $4.61 million foreign-currency translation loss.
- Loss per share: Basic and diluted loss per share was $0.48, compared with $0.37 in the prior period.
- Cash flow: Operating activities used $8.20 million, compared with $6.75 million provided in the prior period. Investing activities used $0.07 million, and financing activities provided $1.60 million. Cash decreased by $8.48 million, including a $1.81 million negative foreign-exchange effect.
- Liquidity: Cash and cash equivalents were $11.25 million at September 30, 2022, down from $19.73 million at March 31, 2022. Current assets were $45.50 million versus current liabilities of $22.64 million.
- Debt and liabilities: Short-term bank borrowings were $2.15 million, compared with $2.27 million at March 31, 2022. Total liabilities increased to $24.41 million from $20.01 million, primarily reflecting higher accounts payable.
- Assets and equity: Total assets declined to $75.97 million from $97.43 million. Total shareholders’ equity declined to $51.55 million from $77.41 million.
Material Changes and Management Commentary
- Healthcare-products revenue increased to $28.10 million from $11.67 million, partly due to newly acquired companies. Automobile sales increased to $16.04 million from $5.59 million as Taochejun operated for a longer period.
- Management attributed significant healthcare-segment losses to COVID-19 impacts, lockdowns, and mass-testing policies in China, and stated that it was optimizing and integrating segments to limit further losses.
- The company reported a two-month manufacturing-facility closure, which contributed to lower research and development expense.
- Operating cash flow turned negative, while accounts payable increased to $18.42 million from $12.16 million and cash declined materially.
- The financial statements are unaudited and may be materially adjusted during the year-end audit.
Subsequent Events, Outlook, and Risks
- On December 27, 2022, the company agreed to sell 3.0 million Class A ordinary shares at $2.00 per share for approximately $6.0 million of gross proceeds. It planned to use 50% for a collaboration with DMG Tech Investment Ltd. and the remainder for general corporate purposes.
- On December 28, 2022, the company entered into a collaboration agreement with DMG relating to licensed animation intellectual property and a proposed joint venture. The company agreed to pay DMG $3.0 million in cash.
- The filing provides no formal revenue, earnings, or cash-flow guidance. Forward-looking statements are subject to general execution, market, regulatory, financing, foreign-exchange, and other uncertainties.
- Key disclosed risks include continued operating losses, weak gross margins, negative operating cash flow, COVID-19-related disruption, reliance on acquired or newly developed businesses, and the need to manage liquidity and funding requirements.
Investor Verification Items
- Verify the correct issuer and whether this filing is relevant to Paranovus Entertainment Technology Ltd., because the filing names Happiness Development Group Limited.
- Reconcile the filing’s inconsistent descriptions of 2021 operating income or loss.
- Review the audited year-end financial statements for adjustments to these unaudited results.
- Assess the sustainability and margins of the healthcare and automobile businesses after the decline in e-commerce revenue.
- Confirm completion, dilution impact, use of proceeds, and related-party or governance terms of the December 2022 private placement and DMG collaboration.
- Evaluate liquidity needs given the cash decline, negative operating cash flow, and increased accounts payable.